Logo

Biomax Investors Say Company to Pursue Buy and Build Strategy

May 30, 2005

NEW YORK, May 30 (GenomeWeb News) - Biomax Informatics expects to pursue an acquisition strategy within the European bioinformatics sector, according to two of the Munich-based company's institutional investors.

 

In October, Biomax raised €2.25 million ($2.75 million) in a round of venture capital funding that included investors Ecos Venture Capital Beteiligungs and S-UBG Bayern Gesellschaft f r Unternehmensbeteiligungen.

 

"Presently, the provider side of the European bioinformatics market is characterized by a few large companies such as Biomax, as well as a multitude of smaller providers and university spin-offs which employ up to 20 people and have an annual revenue of less than €1 million," Frank Zimmermann, manager at S-UBG, said in a statement.

 

"The current development in the bioinformatics market opens new synergies and opportunities for Biomax within the frame of a 'buy and build' strategy," Hans-Juergen Schmitz, director of Ecos, added in the statement. "Thus, we will enable Biomax to play a leading role in the necessary consolidation of the bioinformatics industry in Europe."

 

Breaking News
The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.